β Home
βΉοΈ Info
π§Ύ Overview π Core Facts π₯ Video Blog β Ratings π§βπΌ Executives π¬ My Commentsπ‘ Analytics
π’ Company Q&A π οΈ Industry Q&A π Competitors π Stock Swings β‘ SWOT ποΈ PEST π Porter's Five Forces β¨ Score Positive β οΈ Risks π§© Segmentationπ§ Tools
β Due DiligenceIncome Statement
Pay attention and research significant changes from year to year values. [ ! ]
Fixed Column | Revenue | Cost of Revenue | Gross Profit | Gross Profit Ratio | R&D Expenses | General And Administrative Expenses | Selling And Marketing Expenses | Selling General And Administrative Expenses | Other Expenses | Operating Expenses | Cost And Expenses | Interest Income | Interest Expense | Depreciation And Amortization | EBITDA | EBITDA Ratio | Operating Income | Operating Income Ratio | Total Other Income Expenses Net | Income Before Tax | Income Before Tax Ratio | Income Tax Expense | Net Income | Net Income Ratio | EPS | EPS Diluted | Weighted Average Shares Out | Weighted Average Shares Out Diluted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-12 | 1170611.0 | 339409.0 | 831202.0 | 0.0 | 181440.0 | 0.0 | 110098.0 | 110098.0 | -2338.0 | 289200.0 | 628609.0 | 5.0 | -1027.0 | 0.0 | 542002.0 | 0.46 | 542002.0 | 0.46 | 1032.0 | 543034.0 | 0.46 | 155717.0 | 387317.0 | 0.33 | 0.0 | 0.0 | 0.0 | 0.0 |
2023-12 | 1111367.0 | 413306.0 | 698061.0 | 0.0 | 174868.0 | 0.0 | 112580.0 | 112580.0 | -28561.0 | 258887.0 | 672193.0 | 4647.0 | 0.0 | 4674.0 | 443848.0 | 0.39 | 439174.0 | 0.39 | 4647.0 | 443821.0 | 0.39 | 118349.0 | 325472.0 | 0.29 | 197.8 | 197.8 | 1645.46 | 1645.49 |
2022-12 | 1259946.0 | 476251.0 | 783695.0 | 0.0 | 149626.0 | 23611.0 | 77149.0 | 100760.0 | -2134.0 | 250386.0 | 726637.0 | 182.0 | 61.0 | 31434.0 | 531227.0 | 0.42 | 533309.0 | 0.42 | -2143.0 | 531166.0 | 0.42 | 156737.0 | 374429.0 | 0.29 | 227.64 | 227.57 | 1644.79 | 1645.33 |
2021-12 | 999759.0 | 338147.0 | 661612.0 | 0.0 | 137299.0 | 25824.0 | 76592.0 | 102416.0 | -2540.0 | 239715.0 | 577862.0 | 166.0 | 48.0 | 30868.0 | 419433.0 | 0.41 | 421897.0 | 0.42 | -2512.0 | 419385.0 | 0.41 | 116390.0 | 302995.0 | 0.3 | 184.29 | 184.17 | 1644.15 | 1645.22 |
2020-12 | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** |
2019-12 | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** |
2018-12 | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** |
2017-12 | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** |
2016-12 | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** |
2015-12 | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** |
2014-12 | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** |

π Discover additional income statement data for Chugai Pharmaceutical!
Sign up for free or log in
Have you heard about our short Daily Video Newsletter?
Find out more